HighTide raises US$27.3M to commercialise lead diabetes drug
What's the deal? HighTide Therapeutics has raised US$27.3M in a post-IPO share placing to fund the commercialisation and expansion of its lead drug candidate. The Hong Kong-listed biopharmaceutical company (stock code 2511) placed up to 99 million new shares at US$0.28 each, with China Renaissance Securities acting as sole placing agent.
Why now? HighTide confirmed it had not conducted any equity fundraising in the past 12 months. The placing was signed on July 31, 2026, under a general mandate from the 2026 AGM, meaning no separate shareholder approval was required.
What's the endgame? HighTide develops therapies for cardiovascular-kidney-metabolic diseases. It plans to spend 45% of net proceeds expanding its lead candidate HTD1801 into new indications, including chronic kidney disease, and 30% on commercialising the drug for Type 2 diabetes. The remainder covers other pipeline R&D and working capital, with all funds due to be deployed by the end of 2028.
What could go wrong? The shares were placed at US$0.28, an 11.49% discount to the five-day average price. The new stock represents about 17.33% of existing issued capital, a dilution the company acknowledged could weigh on the share price in the short term.
The signal: The raise marks a step-up for HighTide, giving it capital to move HTD1801 from clinical development toward market. For a metabolic-disease biopharma, funding commercialisation while widening a single asset's indications is a bet on depth over breadth.
Read more: minichart.com.sg
Image credit: jessicafm
